The proportion of patients affected by a fibrotic form of liver disease according to NAFLD fibrosis score, and FIB-4, reduced significantly after 6 months of therapy in the SGLT2 inhibitors group, the main difference with the current study is the fact that they enrolled only patients with fibrosis. This evidence concerns the gene SLC5A2 and liver disorder.